WaferGen Bio-systems, Inc. (WGBS) is a company that specializes in developing and commercializing innovative genomic technologies for life science research, clinical diagnostics, and precision medicine. The company's products are used for gene expression profiling, genotyping, single-cell analysis, and other applications in the field of genomics. WaferGen operates in the United States and Europe, and it offers a range of products and services including the SmartChip System, the ICELL8 Single-Cell System, and the Apollo 324 System.
As of my knowledge cutoff in September 2021, the market capitalization of WGBS was approximately $16.6 million. The company has faced some financial challenges in recent years, including a decline in revenues and an increase in operating expenses. However, WaferGen has also been working to address these challenges through various initiatives, such as cost reductions, new product launches, and strategic partnerships.
Like all stocks, investing in WGBS carries certain risks, including the potential for changes in market conditions, changes in industry trends, and changes in company performance. Investors should carefully consider these risks and conduct thorough research before making any investment decisions.
WaferGen Bio-systems, Inc. (WGBS) is a company that specializes in developing and commercializing innovative genomic technologies for life science research, clinical diagnostics, and precision medicine. The company's products are used for gene expression profiling, genotyping, single-cell analysis, and other applications in the field of genomics. WaferGen operates in the United States and Europe, and it offers a range of products and services including the SmartChip System, the ICELL8 Single-Cell System, and the Apollo 324 System.